CarelonRx, Inc. Sustainability Profile
CarelonRx, Inc., headquartered in the United States, is a prominent player in the pharmacy benefit management industry. Founded in recent years, the company has quickly established itself as a leader in providing innovative pharmacy solutions across major operational regions in the US. Specialising in comprehensive medication management, CarelonRx offers a range of services designed to enhance patient outcomes and streamline pharmacy operations. Their unique approach combines advanced technology with personalised care, setting them apart in a competitive market. With a commitment to improving healthcare accessibility and affordability, CarelonRx has achieved significant milestones, positioning itself as a trusted partner for healthcare providers and patients alike. The company continues to make strides in optimising pharmacy benefits, ensuring that quality care is within reach for all.
DitchCarbon Score
How does CarelonRx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CarelonRx, Inc.'s score of 50 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CarelonRx, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Elevance Health, Inc., and any climate commitments or emissions data would be cascaded from this parent organisation. Elevance Health, Inc. has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for CarelonRx, Inc. are not detailed in the available information. As a subsidiary, CarelonRx, Inc. aligns with Elevance Health's broader sustainability goals, which may include commitments to reduce greenhouse gas emissions across all scopes. Nonetheless, without specific data or targets directly attributed to CarelonRx, Inc., the company's individual climate commitments remain unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 17,050,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 102,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,191,207,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is CarelonRx, Inc.'s Industry?
How Carbon Intensive is CarelonRx, Inc.'s Location?
CarelonRx, Inc.'s Scope 3 Categories Breakdown
CarelonRx, Inc.'s Scope 3 emissions, which increased by 11% last year and decreased by approximately 61% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Capital Goods" being the largest emissions source at 5% of Scope 3 emissions.
Top Scope 3 Categories
CarelonRx, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CarelonRx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
